Trial · NCT02729545

The Efficacy and Safety Study of Tung's Acupuncture for Polycystic Ovarian Syndrome

NCT02729545, Phase 2, Completed, Beijing Hospital of Integrated Traditional Chinese and Western Medicine; results first posted 2019-09-24

3 sourcestrials-2026-11-12-0.5.0

Download JSON

Cite this record

ConductScience Library. The Efficacy and Safety Study of Tung's Acupuncture for Polycystic Ovarian Syndrome. Trials, record NCT02729545. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02729545

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: The Efficacy and Safety Study of Tung's Acupuncture for Polycystic Ovarian Syndrome
NCT number: NCT02729545
Status: Completed
Phases: Phase 2
Enrollment: 60 participants, actual
Lead sponsor: Beijing Hospital of Integrated Traditional Chinese and Western Medicine
Conditions: Polycystic Ovarian Syndrome
Interventions: Tung's acupuncture, Cyproterone acetate/ethinylestradiol (CPA/EE)
First posted: 2016-04-06
Last updated: 2019-10-08
Results first posted: 2019-09-24

Source ClinicalTrials.gov

Registered outcomes9

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Change in LH/FSH Ratio From Baseline to the End of Treatment	baseline and 12 weeks	the change in LH/FSH ratio, values after 12-week treatment minus the values at baseline
Secondary	Change in LH/FSH Ratio From Baseline to the 24th Week	baseline to the 24th week	the change in LH/FSH ratio, values at the 24th week minus the values at baseline
Secondary	Changes in LH From Baseline to the End of Treatment	baseline and 12 weeks	changes in luteinizing hormone(LH), values after 12-week treatment minus the values at baseline
Secondary	Changes in FSH From Baseline to the End of Treatment	baseline and 12 weeks	changes in follicle-stimulating hormone (FSH), values after 12-week treatment minus the values at baseline
Secondary	Changes in Body Mass Index (BMI) From Baseline to the End of Treatment	baseline and 12 weeks	the changes in BMI, values after 12-week treatment minus the values at baseline
Secondary	Changes in Total Testosterone (TT) From Baseline to the End of Treatment	baseline and 12 weeks	changes in total testosterone (TT) , values after 12-week treatment minus the values at baseline
Secondary	Changes in Ovarian Volume From Baseline to the End of Treatment	baseline and 12 weeks	changes in ovarian volume, values after 12-week treatment minus the values at baseline
Secondary	Changes in Polycystic Ovary Number From Baseline to the End of Treatment	baseline and 12 weeks	the changes in polycystic ovary number, values after 12-week treatment minus the values at baseline
Secondary	Changes in the Number of Bleeding Events From Baseline to the End of Treatment	baseline and 12 weeks	Changes in the number of bleeding events, values after 12-week treatment minus the values at baseline

Source ClinicalTrials.gov

Outcomes9

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Change in LH/FSH Ratio From Baseline to the End of Treatment	baseline and 12 weeks	Sixty participants were randomly assigned to acupuncture group (n = 30) or CPA/EE group (n = 30). During the study period, one participant in the acupuncture group withdrew because of living far away from hospital, two participants in the CPA/EE group withdrew because of taking other medicine and health reason.	ratio	MEAN
SECONDARY	Change in LH/FSH Ratio From Baseline to the 24th Week	baseline to the 24th week	During the long-term observation, three participants in the acupuncture group withdrew because of living far away from hospital, pregnancy and taking other medicine. Five participants in the CPA/EE group withdrew because of taking other medicine,pregnancy, losting contact and health reason.	ratio	MEAN
SECONDARY	Changes in LH From Baseline to the End of Treatment	baseline and 12 weeks	Sixty participants were randomly assigned to acupuncture group (n = 30) or CPA/EE group (n = 30). During the study period, one participant in the acupuncture group withdrew because of living far away from hospital, two participants in the CPA/EE group withdrew because of taking other medicine and health reason.	mIU/mL	MEAN
SECONDARY	Changes in FSH From Baseline to the End of Treatment	baseline and 12 weeks	Sixty participants were randomly assigned to acupuncture group (n = 30) or CPA/EE group (n = 30). During the study period, one participant in the acupuncture group withdrew because of living far away from hospital, two participants in the CPA/EE group withdrew because of taking other medicine and health reason.	mIU/mL	MEAN
SECONDARY	Changes in Body Mass Index (BMI) From Baseline to the End of Treatment	baseline and 12 weeks	Sixty participants were randomly assigned to acupuncture group (n = 30) or CPA/EE group (n = 30). During the study period, one participant in the acupuncture group withdrew because of living far away from hospital, two participants in the CPA/EE group withdrew because of taking other medicine and health reason.	kg/m^2	MEAN
SECONDARY	Changes in Total Testosterone (TT) From Baseline to the End of Treatment	baseline and 12 weeks	Sixty participants were randomly assigned to acupuncture group (n = 30) or CPA/EE group (n = 30). During the study period, one participant in the acupuncture group withdrew because of living far away from hospital, two participants in the CPA/EE group withdrew because of taking other medicine and health reason.	nmol/L	MEAN
SECONDARY	Changes in Ovarian Volume From Baseline to the End of Treatment	baseline and 12 weeks	Sixty participants were randomly assigned to acupuncture group (n = 30) or CPA/EE group (n = 30). During the study period, one participant in the acupuncture group withdrew because of living far away from hospital, two participants in the CPA/EE group withdrew because of taking other medicine and health reason.	cm^3	MEAN
SECONDARY	Changes in Polycystic Ovary Number From Baseline to the End of Treatment	baseline and 12 weeks	Sixty participants were randomly assigned to acupuncture group (n = 30) or CPA/EE group (n = 30). During the study period, one participant in the acupuncture group withdrew because of living far away from hospital, two participants in the CPA/EE group withdrew because of taking other medicine and health reason.	polycystic ovaries	MEAN
SECONDARY	Changes in the Number of Bleeding Events From Baseline to the End of Treatment	baseline and 12 weeks	Sixty participants were randomly assigned to acupuncture group (n = 30) or CPA/EE group (n = 30). During the study period, one participant in the acupuncture group withdrew because of living far away from hospital, two participants in the CPA/EE group withdrew because of taking other medicine and health reason.	bleeding events	MEAN

Source ClinicalTrials.gov

Results by group18

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Change in LH/FSH Ratio From Baseline to the End of Treatment	Tung's Acupuncture	-0.66	95% Confidence Interval -1.03 to -0.28	ratio
Change in LH/FSH Ratio From Baseline to the End of Treatment	CPA/EE	-0.96	95% Confidence Interval -1.34 to -0.59	ratio
Change in LH/FSH Ratio From Baseline to the 24th Week	Tung's Acupuncture	-0.39	95% Confidence Interval -0.77 to -0.01	ratio
Change in LH/FSH Ratio From Baseline to the 24th Week	CPA/EE	-0.44	95% Confidence Interval -0.85 to -0.24	ratio
Changes in LH From Baseline to the End of Treatment	Tung's Acupuncture	-3.92	95% Confidence Interval -5.74 to -2.09	mIU/mL
Changes in LH From Baseline to the End of Treatment	CPA/EE	-5.66	95% Confidence Interval -7.84 to -3.48	mIU/mL
Changes in FSH From Baseline to the End of Treatment	Tung's Acupuncture	-0.49	95% Confidence Interval -1.06 to 0.08	mIU/mL
Changes in FSH From Baseline to the End of Treatment	CPA/EE	-0.22	95% Confidence Interval -0.98 to 0.55	mIU/mL
Changes in Body Mass Index (BMI) From Baseline to the End of Treatment	Tung's Acupuncture	-0.90	95% Confidence Interval -1.36 to -0.43	kg/m^2
Changes in Body Mass Index (BMI) From Baseline to the End of Treatment	CPA/EE	-0.44	95% Confidence Interval -0.71 to -0.17	kg/m^2

1 to 10 of 18Source ClinicalTrials.gov

See all 18 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Tung's Acupuncture Group	30
Overall Study	STARTED	CPA/EE Group	30
Overall Study	COMPLETED	Tung's Acupuncture Group	27
Overall Study	COMPLETED	CPA/EE Group	25
Overall Study	NOT COMPLETED	Tung's Acupuncture Group	3
Overall Study	NOT COMPLETED	CPA/EE Group	5

Source ClinicalTrials.gov

Adverse events8

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Transient bruises at the sites of needle insertion	Skin and subcutaneous tissue disorders	Tung's Acupuncture Group	5	30	9
other	Transient bruises at the sites of needle insertion	Skin and subcutaneous tissue disorders	CPA/EE Group	0	30	0
other	post-treatment soreness	Injury, poisoning and procedural complications	Tung's Acupuncture Group	2	30	2
other	post-treatment soreness	Injury, poisoning and procedural complications	CPA/EE Group	0	30	0
other	nausea	Gastrointestinal disorders	Tung's Acupuncture Group	0	30	0
other	nausea	Gastrointestinal disorders	CPA/EE Group	2	30	2
other	Headache	Nervous system disorders	Tung's Acupuncture Group	0	30	0
other	Headache	Nervous system disorders	CPA/EE Group	3	30	3

Source ClinicalTrials.gov

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Tung's Acupuncture Group	0	30
Total, all-cause mortality	CPA/EE Group	0	30
Total, other adverse events	Tung's Acupuncture Group	5	30
Total, other adverse events	CPA/EE Group	4	30
Total, serious adverse events	Tung's Acupuncture Group	0	30
Total, serious adverse events	CPA/EE Group	0	30

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Tung's Acupuncture Group vs CPA/EE Group: deaths from any cause	Trial comparisons
Tung's Acupuncture Group vs CPA/EE Group: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02729545

GET https://conductscience.org/api/trials/v1/NCT02729545/registered

API reference For AI assistants